Lundbeck Takes A Singular View Toward Tackling Challenging CNS Disorders

The Danish drug maker has focused R&D on four CNS specialties under its new CEO and is moving forward two late-stage programs for symptoms of Alzheimer’s disease. Exec VP-Lundbeck Research, USA Stevin Zorn discusses the firm’s R&D strategy in an interview.